menu search

Fda approves agios' mitapivat as first disease-modifying therapy for genetic blood disorder

The FDA approved Agios Pharmaceuticals Inc's (NASDAQ: AGIO) Pyrukynd (mitapivat) for hemolytic anemia in adults with pyruvate ...

February 18, 2022, 5:41 am

Astrazeneca rolls out "unprecedented' three year survival data for imfinzi/treme combo in liver cancer

A combination of tremelimumab and AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab) extended the lives of newly diagnosed patients with unresec...

January 19, 2022, 12:50 pm

Astrazeneca rolls out "unprecedented' three year survival data for imfinzi/treme combo in liver cancer

A combination of tremelimumab and AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab) extended the lives of newly diagnosed patients with unresec...

January 19, 2022, 12:50 pm

Astrazeneca rolls out "unprecedented' three year survival data for imfinzi/treme combo in liver cancer

A combination of tremelimumab and AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab) extended the lives of newly diagnosed patients with unresec...

January 19, 2022, 12:50 pm

Trevali coo resigns

(Kitco News) - Trevali has operations in Canada, Peru, Namibia and Burkina Faso. In 2021 the company ex...

December 17, 2021, 1:28 pm

Trevali coo resigns

(Kitco News) - Trevali has operations in Canada, Peru, Namibia and Burkina Faso. In 2021 the company ex...

December 17, 2021, 1:28 pm

Trevali coo resigns

(Kitco News) - Trevali has operations in Canada, Peru, Namibia and Burkina Faso. In 2021 the company ex...

December 17, 2021, 1:28 pm

Repare therapeutics presents preliminary phase 1 monotherapy clinical data from the ongoing first-in-human phase 1/2 tresr study of rp-3500 in solid tumors at aacr-nci-eortc international conference o

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...

October 8, 2021, 3:10 pm

Repare therapeutics presents preliminary phase 1 monotherapy clinical data from the ongoing first-in-human phase 1/2 tresr study of rp-3500 in solid tumors at aacr-nci-eortc international conference o

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...

October 8, 2021, 3:10 pm

Repare therapeutics presents preliminary phase 1 monotherapy clinical data from the ongoing first-in-human phase 1/2 tresr study of rp-3500 in solid tumors at aacr-nci-eortc international conference o

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...

October 8, 2021, 3:10 pm

New preclinical data supports nuvalent lead programs in ros1-positive, alk-positive nsclc

CAMBRIDGE, Mass., Oct. 7, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted th...

October 7, 2021, 9:21 am

New preclinical data supports nuvalent lead programs in ros1-positive, alk-positive nsclc

CAMBRIDGE, Mass., Oct. 7, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted th...

October 7, 2021, 9:21 am

New preclinical data supports nuvalent lead programs in ros1-positive, alk-positive nsclc

CAMBRIDGE, Mass., Oct. 7, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted th...

October 7, 2021, 9:21 am


Search within

Pages Search Results: